SAB Biotherapeutics announced that the SAB Board of Directors has approved the appointment of Andrew Moin to the Company’s Board of Directors. SAB also announced the closing of the issuance of Series A-1 Preferred Stock, the first tranche of the $130 million in private financing the company announced on Oct. 2. The gross proceeds of the issuance of Series A-1 Preferred Stock are approximately $7.5 million. Moin’s appointment, SAB Biotherapeutics’ Board is composed of nine directors, seven of whom are independent. Moin serves as Partner and Analyst at Sessa Capital, a New York based investment advisor registered with the SEC.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SABS:
- SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors
- SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes
- SAB Biotherapeutics announces private placement of up to $130M
- SAB Biotherapeutics files to sell 1.92M shares of common stock for holders
- SAB Biotherapeutics reports Q2 EPS (14c) vs (11c) last year
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue